Elan shares plunge as another patient dies: Difference between revisions
Jump to navigation
Jump to search
[unchecked revision] | [unchecked revision] |
Content deleted Content added
No edit summary |
DouglasGreen (talk | contribs) m Spellchecked |
||
Line 4: | Line 4: | ||
[[Ireland|Irish]] biotech firm [[w:Élan|Élan]] has seen its shares plunge this morning after it revealed that a fourth patient taking its new [[w:multiple sclerosis|multiple sclerosis]] drug Tysabri had contracted a fatal brain disease. |
[[Ireland|Irish]] biotech firm [[w:Élan|Élan]] has seen its shares plunge this morning after it revealed that a fourth patient taking its new [[w:multiple sclerosis|multiple sclerosis]] drug Tysabri had contracted a fatal brain disease. |
||
Whilst US stockmarkets have not yet opened for business, [[w:Athlone|Athlone]] based Élan has suffered a 22% drop on the [[w:Irish Stock |
Whilst US stockmarkets have not yet opened for business, [[w:Athlone|Athlone]] based Élan has suffered a 22% drop on the [[w:Irish Stock Exchange|Irish Stock Exchange]] and a 21.5% drop on the [[w:London Stock Exchange|London Stock Exchange]]. That means that so far today the firms market value has dropped by over €400mm to €1.9bn. The firm was once valued at over €20bn before the failure of Tysabri and an accounting investigation. |
||
Élan was once one of Ireland's biggest business success stories. Élan still employs over 2,000 people in Ireland and reported revenues of $464.0 million in 2004. |
Élan was once one of Ireland's biggest business success stories. Élan still employs over 2,000 people in Ireland and reported revenues of $464.0 million in 2004. |
||
==Related Stories== |
==Related Stories== |
Revision as of 06:20, 3 June 2005
Thursday, June 2, 2005
Irish biotech firm Élan has seen its shares plunge this morning after it revealed that a fourth patient taking its new multiple sclerosis drug Tysabri had contracted a fatal brain disease.
Whilst US stockmarkets have not yet opened for business, Athlone based Élan has suffered a 22% drop on the Irish Stock Exchange and a 21.5% drop on the London Stock Exchange. That means that so far today the firms market value has dropped by over €400mm to €1.9bn. The firm was once valued at over €20bn before the failure of Tysabri and an accounting investigation.
Élan was once one of Ireland's biggest business success stories. Élan still employs over 2,000 people in Ireland and reported revenues of $464.0 million in 2004.
Related Stories
- "Elan; Biogen withdraw multiple sclerosis drug after death" — Wikinews, March 1, 2005
Sources
- "Elan shares fall on reported fourth PML case" — RTE News, June 2, 2005
- "Elan falls on new report of Tysabri-linked illness" — Reuters, June 2, 2005
- Jeffrey Krasner. "A fourth death may be tied to Biogen's MS drug" — Boston Globe, June 2, 2005